<DOC>
	<DOCNO>NCT01078155</DOCNO>
	<brief_summary>This post marketing observational study conduct prospective , single country , multicenter format ass prevention generalize bone loss patient active rheumatoid arthritis ( RA ) treat adalimumab ( Humira® ) pragmatic prescribing situation . The investigational site center experience treatment RA patient anti-tumor necrosis factor-alpha ( TNF-a ) therapy . The investigator rheumatologists authorized Czech Rheumatologic Society prescribe biological treatment .</brief_summary>
	<brief_title>Evaluation Role Adalimumab Extraarticular Manifestation - Bone Metabolism Bone Mineral Density Patients With Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Patients active early longstanding RA accord American College Rheumatology ( ACR ) 1987 revise criterion . Patients high disease activity DAS28 ≥ 5.1 accord Czech Rheumatological Society criterion . Patients must fulfill national guideline use antiTNF : inadequate clinical response least one diseasemodifying antirheumatic drug ( DMARD ; methotrexate , sulphasalazine , leflunomide , hydroxychloroquine , combination ) oral glucocorticoid ( equivalent ≥ 5 mg prednisolone per day ) , ( Romania except glucocorticoid ) ; chest Xray , purify protein derivative ( PPD ) skin test , Quantiferon/tuberculosis ( TB ) Gold test ( available ) negative TB . Patients history TNF block rituximab therapy . Patients treat treated drug risk interaction adalimumab ( Humira ) . Pregnant female and/or female without adequate method contraception . Patients n't receive prior DMARD therapy . Patients participate another study clinical trial . Patients severe osteoporosis ( Tscore [ number indicate whether bone loss occur ] ≤ 2.5 and/or prior vertebral fracture/s ) . Patients history total hip replacement extremity . Patients currently receive and/or receive bone metabolism modulate agent include Selective Estrogen Receptor Modulators ( SERMs ) , bisphosphonates , parathyroid hormone antireceptor activator nuclear factorkappaB ligand ( RANKL ) therapy . Subjects eligible TNFblocking therapy accord Czech National Registry ( ATTRA ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Bone mineral density</keyword>
	<keyword>Bone turnover marker</keyword>
	<keyword>Rheumatoid arthritis</keyword>
	<keyword>Osteoporosis</keyword>
</DOC>